

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



RTMP
copy

SG 9701138-1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/55, 31/535, 31/445, 31/40, 31/21, 31/26, 31/135	A1	(11) International Publication Number: WO 96/09051 (43) International Publication Date: 28 March 1996 (28.03.96)
(21) International Application Number: PCT/US95/12345 (22) International Filing Date: 18 September 1995 (18.09.95) (30) Priority Data: 08/308,904 20 September 1994 (20.09.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/308,904 (CON) Filed on 20 September 1994 (20.09.94) (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indi- anapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BRYANT, Henry, Uhlman [US/US]; 7840 Camelback Drive, Indianapolis, IN 46250 (US). FONTANA, Steven, Anthony [US/US]; 2006 Foxcliff North, Martinsville, IN 46151 (US). (74) Agent: LAMMERT, Steven, R.; Barnes & Thornburg, 1313 Merchants Bank Building, 11 South Meridian Street, Indi- anapolis, IN 46204 (US).		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A METHOD FOR MINIMIZING THE UTEROTROPHIC EFFECT OF TAMOXIFEN AND TAMOXIFEN ANALOGS		
(57) Abstract The present invention provides a method of minimizing the uterotrophic effect of non-steroidal triphenylethylene, antiestrogenic compounds, when such compounds are administered for the treatment or prevention of breast carcinoma, via the coadministration of certain antiestrogenic naphthyl compounds. Pharmaceutical compositions are also provided.		